Novo Nordisk's Alhemo (concizumab) receives a positive opinion from the EMA's CHMP for hemophilia A or B with inhibitors. The ...

The European stock markets closed mostly higher on Friday as the Stoxx Europe 600 gained 0.19%, the Swiss Market Index was up 0.18%, France's CAC rose 0.39%, Germany's increased 0.38%, while the FTSE ...

U.S. consumer groups and two large labor unions urged the U.S. Federal Trade Commission on Thursday to block Novo Holdings, ...

This week marked the start of the third-quarter earnings season, with Johnson & Johnson exceeding Wall Street’s expectations.

The "takings clause" in the Fifth Amendment to the U.S. Constitution might keep the federal government from creating ...

Amgen (NASDAQ: AMGN) stock is up 13% this year but has struggled to break out above a tight trading range in recent months.

Prothena Corporation plc's stock has dropped 67% since my last “Buy” rating, primarily due to delays and a lack of meaningful ...

As global markets navigate a complex landscape marked by record highs in U.S. indices and mixed economic signals from Europe ...

On Oct. 15, J&J JNJ announced strong third-quarter results, beating estimates for both earnings and sales. The Innovative ...

Novo Nordisk's Alhemo drug has been recommended for European approval as a treatment for hemophilia, the company said Friday.

Weight-loss drugs such as Ozempic, made by Denmark's Novo Nordisk, can reduce rates of opioid and alcohol abuse by up to 50%, according to a new study that supports expectations the drugs can offer ...

Paul Harris of Harris Douglas Asset Management says he hasn’t sold a stock since 2020. ‘I don’t feel the need to sell ...